Data as of Sep 19
| +0.13 / +4.81%|
The 5 analysts offering 12-month price forecasts for Corcept Therapeutics Inc have a median target of 2.00, with a high estimate of 6.00 and a low estimate of 1.50. The median estimate represents a -29.33% decrease from the last price of 2.83.
The current consensus among 5 polled investment analysts is to Hold stock in Corcept Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.